Long‐term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP‐ritux
- 5 September 2019
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 94 (12), 1314-1324
- https://doi.org/10.1002/ajh.25632
Abstract
Rituximab is a second‐line option in adults with immune thrombocytopenia (ITP), but the estimated 5‐year response rate, only based on pooled retrospective data, is about 20%, and no studies have focused on long‐term safety. We conducted a prospective multicenter registry of 248 adults with ITP treated with rituximab with 5 years of follow‐up to assess its long‐term safety and efficacy. The median follow‐up was 68.4 [53.7‐78.5] months. The incidence of severe infections was only 2/100 patient‐years. Profound hypogammaglobulinemia (<5 g/L) developed in 5 patients at 15 to 31 months after the last rituximab infusion. In total, 25 patients died at a median age of 80 [69.5‐83.9] years, corresponding to a mortality rate of 2.3/100 patient‐years. Only 3 deaths related to infection that occurred 12 to 14 months after rituximab infusions could be due in part to rituximab. At 60 months of follow‐up, 73 (29.4%) patients had a sustained response. On univariate and multivariate analysis, the only factor significantly associated with sustained response was a previous transient response to corticosteroids (p=0.022). Overall, 24 patients with an initial response and then relapse received retreatment with rituximab, which gave a response in 92%, with a higher duration of response in 54%. As a result of its safety profile and its sustained response rate, rituximab remains an important option in the current therapeutic armamentarium for adult ITP. Retreatment could be an effective and safe option.Keywords
This publication has 57 references indexed in Scilit:
- Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patientsAnnals Of The Rheumatic Diseases, 2012
- Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopeniaBlood, 2012
- A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopeniaBlood, 2012
- Neutropenia associated with rituximab therapyCurrent Opinion in Hematology, 2011
- Repeated courses of rituximab in chronic ITP: Three different regimensAmerican Journal of Hematology, 2009
- The ITP syndrome: pathogenic and clinical diversityBlood, 2009
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectBlood, 2009
- Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working groupBlood, 2009
- Autoimmunity and Susceptibility to Hodgkin Lymphoma: A Population-Based Case–Control Study in ScandinaviaJNCI Journal of the National Cancer Institute, 2006
- Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITPBlood, 2004